These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24314359)

  • 1. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(6):615-25. PubMed ID: 24314359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(3):199-207. PubMed ID: 23725919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.
    Su TC; Hwang JJ; Huang KC; Chiang FT; Chien KL; Wang KY; Charng MJ; Tsai WC; Lin LY; Vige R; Olivar JE; Tseng CD
    J Atheroscler Thromb; 2017 Mar; 24(3):275-289. PubMed ID: 27600795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study.
    Tatsuno I; Kudou K; Kagawa T
    Cardiovasc Ther; 2015 Dec; 33(6):317-23. PubMed ID: 26222126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
    Backes J; Anzalone D; Hilleman D; Catini J
    Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.
    Peters BS; Wierzbicki AS; Moyle G; Nair D; Brockmeyer N
    Clin Ther; 2012 Jan; 34(1):67-76. PubMed ID: 22212377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
    Maki KC; Bays HE; Ballantyne CM; Underberg JA; Kastelein JJP; Johnson JB; Ferguson JJ
    J Am Heart Assoc; 2022 Mar; 11(6):e024176. PubMed ID: 35232215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
    Weintraub HS
    Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial.
    Qi L; Zhang Q; Zheng Z; Pei Z; Mao H; Jiang T; Kazei D; Kahler E; Huo Y
    Vasc Health Risk Manag; 2021; 17():571-580. PubMed ID: 34552329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids.
    Brunton S; Collins N
    Curr Med Res Opin; 2007 May; 23(5):1139-45. PubMed ID: 17519081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
    Kim ES; McCormack PL
    Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study.
    Mori T; Murasaki K; Yokoyama Y
    J Clin Lipidol; 2022; 16(5):737-746. PubMed ID: 36202740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies
    Lopez-Toledano MA; Thorsteinsson T; Daak A; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
    Clin Ther; 2017 Mar; 39(3):581-591. PubMed ID: 28189364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study.
    Mori T; Murasaki K; Hayashi K; Yokoyama Y
    J Clin Lipidol; 2022; 16(5):704-714. PubMed ID: 35871058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription n-3 fatty acids, but not eicosapentaenoic acid alone, improve reference memory-related learning ability by increasing brain-derived neurotrophic factor levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model.
    Hashimoto M; Inoue T; Katakura M; Tanabe Y; Hossain S; Tsuchikura S; Shido O
    Neurochem Res; 2013 Oct; 38(10):2124-35. PubMed ID: 23963508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
    Maki KC; Johns C; Harris WS; Puder M; Freedman SD; Thorsteinsson T; Daak A; Rabinowicz AL; Sancilio FD
    Clin Ther; 2017 Mar; 39(3):652-658. PubMed ID: 28189365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
    Fialkow J
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
    Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.